Navigation Links
Monogram Biosciences Announces Immediate Availability of Enhanced Sensitivity Trofile(TM) HIV Tropism Assay
Date:6/5/2008

ed; whether the FDA or any other agency will decide to further regulate our products or services, including Trofile; whether the draft guidance on Multivariate Index Assays issued by FDA will be subsequently determined to apply to our current or planned products; whether we will encounter problems or delays in automating our processes; the ultimate validity and enforceability of our patent applications and patents; the possible infringement of the intellectual property of others; whether licenses to third party technology will be available; whether we are able to build brand loyalty and expand revenues; restrictions on the conduct of our business imposed by the Pfizer, Merrill Lynch and other debt agreements; the impact of additional dilution if our convertible debt is converted to equity; and whether we will be able to raise sufficient capital in the future, if required. For a discussion of other factors that may cause actual events to differ from those projected, please refer to our most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other subsequent filings with the Securities and Exchange Commission. We do not undertake, and specifically disclaim any obligation, to revise any forward-looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements.

Trofile is a trademark of Monogram Biosciences, Inc. Selzentry is a trademark of Pfizer Inc.

contacts: Alfred G. Merriweather Jeremiah Hall

Chief Financial Officer Feinstein Kean Healthcare

Tel: 650 624 4576 Tel: 415 677 2700

amerriweather@ jeremiah.hall@

monogrambio.com fkhealth.com


'/>"/>
SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Monogram Announces First Medicare Payment for Trofile(TM)
2. Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference
3. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
4. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
5. Pressure BioSciences to Present at the Rodman & Renshaw BioFin 9th Annual Healthcare Conference in New York City on November 5th
6. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
7. Pressure BioSciences, Inc. to Discuss Third Quarter Financial Results and Provide Business Update
8. Anaptys Biosciences Raises Over $33 Million in Series B Financing
9. YM BIOSCIENCES REPORTS FIRST QUARTER 2008 OPERATIONAL AND FINANCIAL RESULTS
10. Pressure BioSciences, Inc. Reports Third Quarter 2007 Financial Results and Provides Business Update
11. Schering-Plough Receives Clearance From U.S. Federal Trade Commission for Planned Acquisition of Organon Biosciences N.V.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... (PRWEB) July 22, 2014 Garland’s new ... is designed to be used as a flood coat ... systems or as a premium restoration material. It provides ... the long-term performance and reducing life-cycle costs. Energizer BK ... to provide excellent water resistance in addition to superior ...
(Date:7/22/2014)... The hair transplant experts at WeGrowHair.com ... assisted laser therapy and robotic assisted hair transplantation ... women suffering from hair loss. Alongside their unique ... Unit Extraction (FUE) procedures via ARTAS – the ... technology, their doctors use advanced digital mapping to ...
(Date:7/21/2014)... sports in the United States, with more than 170,000 ... participation numbers, however, mean that more young people than ... and competition. , In a study published online today ... and available in an upcoming print issue, researchers from ... Children,s Hospital and the Colorado School of Public Health ...
(Date:7/21/2014)... July 21, 2014 As reported by ... Westin Hotel to Raise Addiction Awareness (7/15), thrill-seeking participants ... down a 27-story building in Downtown Philly. 100 people, ... event at the Westin Convention Center Hotel. Some of ... addiction. One man participated because his son killed himself ...
(Date:7/21/2014)... who have a clot in their legs and ... blood-thinning medication or undergo a minimally-invasive catheter-based clot ... no difference in death rates between the two ... the catheter procedure, according to a study by ... involved a review of more than 90,000 cases ...
Breaking Medicine News(10 mins):Health News:Energizer® BK Waterproof Coating from Garland Canada Reduces Life-Cycle Costs 2Health News:WeGrowHair.com/PAI Medical Group Introduces Robotic Assisted Laser Therapy to Treat Hair Loss 2Health News:New study finds high school lacrosse players at risk for concussions, other injuries 2Health News:New study finds high school lacrosse players at risk for concussions, other injuries 3Health News:100 People Climb Down Building to Raise Drug Addiction Awareness in Philadelphia 2Health News:100 People Climb Down Building to Raise Drug Addiction Awareness in Philadelphia 3Health News:Temple study compares deep vein thrombosis therapies 2Health News:Temple study compares deep vein thrombosis therapies 3Health News:Temple study compares deep vein thrombosis therapies 4
... international HIV and AIDS charity AVERT is today launching Stop ... to the 380,000 child AIDS deaths and half a ... ,At this year's G8 summit in Germany, the leaders ... to stop child AIDS deaths by committingspecific funds for prevention ...
... mental well being of young children of today seems to ... NCH, the childrens charity, found that one in ten ... significant level. ,The research says that More than a ... number in a generation. Emotional problems and conduct disorders have ...
... Washington University School of Medicine in St. Louis have ... by revealing that smoking interferes with ligament healing. ... model and found that cigarette smoking impairs the recruitment ... following ligament repair surgery. ,The researchers ...
... More than 60 people had to be treated in hospital ... a polluted Chinese river, state media reported Wednesday. ... their clothes in the Jindong River in eastern Anhui province ... few hours later, Xinhua news agency reported. ,The ...
... have found that a particular resonance pattern in the ... ability to discriminate speech. ,In the ... and Huan Luo report that the inherent rhythm of ... sentences by changing its phase. ,The researchers ...
... recalls how she lost her father, mother and father-in-law to ... to Panama from China. "It's very painful. The three had ... she says, her voice shaking with emotion. ,The ... found to be tainted. At least 80 people in Panama ...
Cached Medicine News:Health News:AIDS Charity AVERT Launches Stop AIDS in Children Campaign 2Health News:Mental Health of Children on the Decline 2Health News:Smoking Hampers Healing of the Ligament 2Health News:Dozens of Panamanians Gravely Ill from Toxic Substance from China 2
(Date:7/21/2014)...  Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ) ... (FDA) accepted the company,s Investigational New Drug (IND) application ... efficacy of AVP-786, Avanir,s next generation compound. The company ... adjunctive treatment of major depressive disorder (MDD) during the ... endorsement of this Phase II study by the division ...
(Date:7/21/2014)... 21, 2014 Sorrento Therapeutics, Inc. (NASDAQ: ... developing new treatments for cancer and its associated pain, ... the preclinical development of a small molecule inhibitor targeting ... The Myc protein has also been recognized as an ... is involved as a dominant factor in most human ...
(Date:7/21/2014)... LA JOLLA, Calif. , July 21, 2014 ... RGLS ), a biopharmaceutical company leading the discovery ... today that the U.S. Food & Drug Administration ... a single stranded, chemically modified oligonucleotide that binds ... as a therapeutic for the treatment of Alport ...
Breaking Medicine Technology:Avanir Pharmaceuticals Announces FDA Acceptance of IND for AVP-786 for the Adjunctive Treatment of Major Depressive Disorder 2Avanir Pharmaceuticals Announces FDA Acceptance of IND for AVP-786 for the Adjunctive Treatment of Major Depressive Disorder 3Avanir Pharmaceuticals Announces FDA Acceptance of IND for AVP-786 for the Adjunctive Treatment of Major Depressive Disorder 4Avanir Pharmaceuticals Announces FDA Acceptance of IND for AVP-786 for the Adjunctive Treatment of Major Depressive Disorder 5Sorrento Awarded Grant from the National Institutes of Health for the Development of a Small Molecule Myc Inhibitor 2Sorrento Awarded Grant from the National Institutes of Health for the Development of a Small Molecule Myc Inhibitor 3Sorrento Awarded Grant from the National Institutes of Health for the Development of a Small Molecule Myc Inhibitor 4Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 2Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 3Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 4Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 5
... Inc. (OTCPK: SNDY) is pleased to announce that the Company ... in the amount of $90,005. The revenue for the three ... fifty Hospitals, Clinics, Healthcare Centers, Medical Centers and Surgery Centers ... growth in 2011 through new product development, new product sales ...
... Ireland, Jan. 27, 2011 Tibotec Pharmaceuticals today ... to generic manufacturers including Hetero Drugs Limited, Matrix ... Aspen Pharmacare of South Africa to manufacture, market ... rilpivirine hydrochloride (TMC278), pending ...
Cached Medicine Technology:Solos Endoscopy, Inc. Reports $90,005 in Sales Revenue for Fourth Quarter 2010 2Tibotec Signs Multiple Agreements With Generic Manufacturers to Provide Access to New HIV Treatment 2Tibotec Signs Multiple Agreements With Generic Manufacturers to Provide Access to New HIV Treatment 3Tibotec Signs Multiple Agreements With Generic Manufacturers to Provide Access to New HIV Treatment 4